Source: Financial Modeling Prep · peers by sector/industry
Insider activity (SEC Form 4)
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Valuation
Trading at 5.0× sales vs its 2.9× historical median P/S.
Fair value ≈ $2.28 · price $3.87 today
Overvalued · 69% above
Loading valuation…
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
$ICAD NASDAQ Equity Corporate Actions Alert # 2025 - 375
Information Regarding the Merger of iCAD, Inc. (ICAD)
https://www.nasdaqtrader.com/TraderNews.aspx?id=ECA2025-375
At a special meeting held on July 14, 2025, the shareholders of iCAD, Inc. (ICAD) approved the proposed merger with and into RadNet, Inc. $RDNT The merger is tentatively scheduled to close prior to the market open on July 17, 2025. In anticipation of the closing, the stock will be halted immediately following the after-hours session at or around 7:50 p.m. on July 16, 2025. If the merger closes as anticipated, the stock will remain halted on the day of closing (July 17th) and will be suspended effective July 18, 2025.
Merger consideration is 0.0677 shares of RDNT for each share of ICAD held.
$ICAD $ICAD has partnered with Microsoft Corporation $MSFT to integrate its ProFound Breast Health Suite into Microsoft’s Precision Imaging Network (PIN), expanding access to AI powered mammography solutions across 1000'S of radiology centers.
“We are excited to partner with Microsoft to expand access to our AI solutions for breast cancer detection across a broader network of healthcare providers,” said Dana Brown, CEO and President of iCAD. “This collaboration supports our growth strategy by expanding the reach of our industry-leading technology and advancing our transition to a SaaS model.”
The platform now supports direct integration into PowerScribe, one of the most widely used radiology reporting tools in the US, enabling standardized reporting and AI-enhanced breast cancer detection. The collaboration is also tied to iCAD’s recently FDA-cleared ProFound Detection Version 4.0, which leverages deep learning to improve performance on dense breast tissue & reduce false positives.
$ICAD partners with $MSFT https://www.barchart.com/story/news/32104285/icad-collaborates-with-microsoft-to-provide-access-to-its-mammography-solutions-in-microsofts-precision-imaging-network-pin
